Khiron Life Sciences has announced a bought deal equity financing at $2.20 per share to raise $20 Million. They will use the Offering to expand the Company's operating capacity and for working capital requirements and other general corporate purposes.
READ RELEASE BELOW:
Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, and including Cormark Securities Inc. under which the Underwriters have agreed to purchase 9,100,000 common shares of the Company on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.20 for gross proceeds of $20,020,000.
The Company has also granted the Underwriters an over-allotment option to purchase up to an additional 15% of the Common Shares at the Issue Price, exercisable in whole or in part at any time on or up to 30 days following the closing of the Offering. If this option is exercised in full, the Company will receive an additional $3,003,000 in gross proceeds for total aggregate gross proceeds of $23,023,000.
The Company intends to use the net proceeds of the Offering to expand the Company's operating capacity and for working capital requirements and other general corporate purposes.
In connection with the Offering the Company has agreed to pay the Underwriters a cash commission equal to 6.0% of the gross proceeds raised from the Offering (including on any exercise of the Over-Allotment Option), and non-transferable broker warrants equal to 6.0% of the Common Shares sold under the Offering (including on any exercise of the Over-Allotment Option). Each broker warrant will be exercisable at the Issue Price to acquire one Common Share for a period of 24 months following the closing of the Offering.
The closing date of the Offering is scheduled to be on or about February 28, 2019 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange ("TSXV") and the applicable securities regulatory authorities.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
Khiron is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSXV, becoming one of the first Colombian-based medical cannabis companies to trade on any exchange globally.
With a focused regional strategy and patient-oriented approach, Khiron combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron can be found at https://investors.khiron.ca/